homevideos Newshealthcare NewsNot getting any investor for the CRAMS business, says Suven Life Sciences
Not getting any investor for the CRAMS business, says Suven Life Sciences
Venkat Jasti, the chairman and CEO of Suven Life Sciences, spoke to CNBC-TV18 about the company's business plans and growth prospects.
Venkat Jasti, the chairman and CEO of Suven Life Sciences, spoke to CNBC-TV18 about the company's business plans and growth prospects.
“We have announced the demerger of Suven Life Sciences into CRAMS. We have started a US company Suven Pharma. It has more than 120 active products under abbreviated new drug applications (ANDA) development,” Jasti said on Tuesday.
In terms of Rising Pharma’s ANDAs, he added, “121 are commercialised and other 89 are under development.”
Speaking about the company’s plan with the contract research and manufacturing services (CRAMS) business, Jasti said, “As of now, we are not getting any investor.”
The CRAMS business is the bread earner for the company and has grown strongly over the last three years, according to a note by Kotak Securities.
On SUVN-502, Alzheimer drug development, Jasti said, “We have enrolled 550 patients. We are hoping to present our data in mid-July in the Alzheimer’s conference in Los Angeles.”
First Published: Mar 12, 2019 1:20 PM IST
Check out our in-depth Market Coverage, Business News & get real-time Stock Market Updates on CNBC-TV18. Also, Watch our channels CNBC-TV18, CNBC Awaaz and CNBC Bajar Live on-the-go!
Over 50 onion farmers detained in Nashik ahead of PM Modi's visit
May 16, 2024 11:14 AM
Why Google CEO is cautiously optimistic about the election year
May 16, 2024 9:51 AM
Mark Mobius reveals how markets will react if NDA wins 400+ Lok Sabha seats
May 15, 2024 8:09 PM